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5LETTER TO THE EDITOR
e: Allogeneic Transplantation after
onmyelosuppressive Conditioning—
he Effect of Single-Agent Pentostatin
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dReduced-intensity preparative regimens for allo-
eneic transplantation have been used to provide suf-
cient immunosuppression to allow for successful do-
or engraftment. In a recent article by Chan et al. [1],
8 patients with myelodysplasia underwent allogeneic
rogenitor cell transplantation with a novel prepara-
ive regimen of extracorporeal photopheresis, total
ody irradiation, and pentostatin. The pentostatin was
iven by continuous infusion over 2 days at 4 mg/m2.
he relative contribution of each agent in achieving
mmunosuppression of the donor was not assessed.
ecent work suggests that successful nonmyeloabla-
ive regimens may be developed free of total body
rradiation and that single-agent pentostatin may be
ufﬁcient to achieve donor chimerism.
We initiated a phase I/II clinical trial to assess the
easibility and safety of related allogeneic progenitor
ell transplantation after nonmyeloablative, reduced-
ntensity preparative conditioning with single-agent
entostatin. Four patients with metastatic renal cell
ancer underwent conditioning with pentostatin 1.75
g/m2 (3 patients) or 2.5 mg/m2 (1 patient) delivered
y bolus intravenous injection every other day for 3
oses on days 7, 5, and 3 before infusion of
able 1. Renal Cancer Trial
Patient
No.
Dose of
Pentostatin
(mg/m2 QOD  3)
No. of CD34
Cells ( 106/kg)
Donor Le
Infusion (
Transpla
1 1.75 9.42 


2 1.75 4.18 

3 1.75 4.11 




2
2
4 2.5 4.7 


OD indicates every other day; GVHD, graft-versus-host disease.
Patient died of progressive metastatic renal carcinoma on day 66.
76ranulocyte colony-stimulating factor–mobilized allo-
eneic hematopoietic progenitor cells. Posttransplan-
ation immunosuppression consisted of cyclosporine
tarted on day 1 at 3 mg/kg and continued at 2
g/kg/d as a continuous infusion until day 30 or
eyond as needed for development of graft-versus-
ost disease. Patients were observed by immunophe-
otype of lymphocyte subsets and for engraftment by
ither ﬂuorescent in situ hybridization for Y chromo-
ome if sex discordant, or restriction fragment length
olymorphism if sex matched, weekly for 4 weeks and
hereafter as clinically indicated. Patients were eligible
or infusion of unstimulated donor leukocytes 1
onth after transplantation for incomplete hemato-
oietic chimerism.
Although the preparative regimen produced sig-
iﬁcant suppression of the CD4 count, there was no
reatment-related myelosuppression despite the slow
evelopment of donor chimerism. At the lowest dose
evel of pentastatin full hematopoietic engraftment
as demonstrated after unstimulated donor leukocyte
nfusion in 2 of 3 patients. At the 2.5 mg/m2 dose,
nstimulated donor leukocyte infusion was given on
ay 51, when restriction fragment length polymor-
e
er
)
Dose of Donor
Leukocytes
(CD3  106/kg)
Time to Full
Donor
Chimerism (day)
Time to Onset
of Acute GVHD
(day)
1.48 101 71
1.47 63 —*
5.86
1.77 59 57ukocyt
day aft
ntation
37
38
39
52
53
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Letter to the Editor
Bhism analysis showed mixed chimerism. The recipi-
nt achieved full donor chimerism by day 59. The
egimen was not associated with myelosuppression,
nd among those who achieved full donor chimerism,
shift from recipient to donor hematopoiesis was
radual and not associated with appreciable neutrope-
ia or thrombocytopenia. Furthermore, the pace of
onor chimerism and time to development of graft-
ersus-host disease were delayed in all 3 patients who
chieved evidence of engraftment, as demonstrated in
able 1.
Notwithstanding the small number of patients,
hese results suggest that single-agent pentostatin may
rove an acceptable preparative agent for reduced-
ntensity allogeneic transplantation, obviating the
eed for costly radiation-containing regimens. Such a
ingle-agent preparative regiment may be of particular
alue for adoptive immunotherapy of solid tumors,
uch as metastatic renal cancer, in which chemother-
py may play a minimal role in antitumor responsesB&MT2]. The preparative regimen may also be useful for
herapy of nonmalignant conditions, because it may be
iven to outpatients and may not be associated with
yelosuppression or signiﬁcant regimen-related tox-
city.
ary J. Schiller, MD
ose Malone, RN
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os Angeles, CA
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